Showing results (11-20 of 96) with videos related to
Sort By:
Pageof 10
Herz|September 2, 2004
[Inflammation and atherogenesis in diabetes mellitus - new therapeutic approaches]Wolfgang Otter, Eberhard Standl, Oliver SchnellDiabetes/Metabolism Research and Reviews|January 3, 2013
What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and ConsEberhard Standl, Michael Erbach, Oliver SchnellDiabetes Care|April 29, 2011
Postprandial hyperglycemia and glycemic variability: should we care?Eberhard Standl, Oliver Schnell, Antonio CerielloJournal of Diabetes and Its Complications|May 14, 2010
The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go lowKatrien Benhalima, Eberhard Standl, Chantal MathieuCurrent Treatment Options in Cardiovascular Medicine|October 7, 2014
Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Eberhard Standl, Michael Erbach, Oliver SchnellDiabetes Technology & Therapeutics|May 14, 2008
How would patients behave if they were continually informed of their blood glucose levels? A simulation study using a "virtual" patientEberhard Biermann, Katharina Barkhausen, Eberhard StandlCirculation Research|May 28, 2016
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 DiabetesEberhard Standl, Oliver Schnell, Darren K McGuireCardiovascular Diabetology|October 8, 2016
Current perspectives on cardiovascular outcome trials in diabetesOliver Schnell, Lars Rydén, Eberhard Standl, et al.Cardiovascular Diabetology|November 17, 2017
Correction to: Updates on cardiovascular outcome trials in diabetesOliver Schnell, Lars Rydén, Eberhard Standl, et al.Cardiovascular Diabetology|October 13, 2017
Updates on cardiovascular outcome trials in diabetesOliver Schnell, Lars Rydén, Eberhard Standl, et al.Pageof 10